Tumor-draining lymph nodes (DLN) are the most important priming sites for generation of antitumor immune responses. They are also the location where an immunosuppressive
cytokine,
transforming growth factor-beta (
TGF-beta), plays a critical role in suppressing these antitumor immune responses. We focused on
TGF-beta-mediated immunosuppression in DLNs and examined whether local inhibition of
TGF-beta augmented antitumor immune responses systemically in
tumor-bearing mice models. For inhibition of
TGF-beta-mediated immunosuppression in DLNs, C57BL/6 mice subcutaneously bearing E.G7
tumors were administered plasmid
DNA encoding the extracellular domain of
TGF-beta type II receptor fused to the human
IgG heavy chain (TGFR
DNA) i.m. near the established
tumor. In DLNs, inhibition of
TGF-beta suppressed the proliferation of regulatory T cells and increased the number of
tumor antigen-specific CD4(+) or CD8(+) cells producing IFN-gamma. Enhancement of antitumor immune responses in DLNs were associated with augmented
tumor antigen-specific cytotoxic and natural killer activity in spleen as well as elevated levels of
tumor-specific antibody in sera. The growth of the established metastatic as well as primary
tumors was effectively suppressed via augmented antitumor immune responses. Inhibition of
TGF-beta-mediated immunosuppression in DLNs is significantly associated with augmented antitumor responses by various immunocompetent cell types. This animal model provides a novel rationale for molecular
cancer therapeutics targeting
TGF-beta.